Impact Factor 6.244 | CiteScore 3.9
More on impact ›
Frontiers in Oncology- Furthering our insight into carcinogenesis and tumor progression, to bridge the gap between basic research and clinical application.
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Indexed in Web of Science (SCIE), Scopus, and PubMed
Frontiers in Oncology publishes rigorously peer-reviewed research advancing our knowledge of cancer epidemiology, molecular pathways, diagnosis and imaging, personalized therapeutics, and novel treatment and management strategies.
Field Chief Editor Giuseppe Giaccone at Weill Cornell Medicine, Cornell University is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific advancement and impactful discoveries on the field of oncology to researchers, academics, clinicians, and the public worldwide..
Frontiers in Oncology welcomes contributions in the various domains of cancer research, from basic research to clinical studies. The journal is composed of different specialty sections and authors are kindly requested to consider the specific requirements of the most adequate specialty for their submission.
Most notably, manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Frontiers in Oncology is a member of the Committee on Publication Ethics.
Short Name: Front. Oncol.
Electronic ISSN: 2234-943X
Indexed in: PubMed, PubMed Central (PMC), Scopus, Web of Science Science Citation Index Expanded (SCIE), Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), CLOCKSS
PMCID: all published articles receive a PMCID
Frontiers in Oncology is composed of the following Specialty Sections:
The specialty sections of Frontiers in Oncology welcome submission of the following article types: Clinical Trial, Correction, Editorial, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Systematic Review, Technology and Code, Brief Research Report, Case Report, Data Report, Erratum, General Commentary, Study Protocol, Retraction and Classification.
When submitting a manuscript to Frontiers in Oncology, authors must submit the material directly to one of the specialty sections. Manuscripts are peer-reviewed by the Associate and Review Editors of the respective specialty section.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact email@example.com
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact firstname.lastname@example.org